The most common and best characterized form of ibrutinib resistance is represented by genetic alteration, with mutations within BTK and its downstream substrate PLCG2, which can be found in CLL clones or subclones of variable size. Here, BTK is linked to B-cell chronic lymphocytic leukemia.